GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

Announces Exclusive Licensing Partnerships for Proprietary Regulatory T Cell Engineering Technologies with Seattle Children's Research Institute, Benaroya Research Institute and MIGAL Galilee Research Institute

BOSTON, SEATTLE and QIRYAT SHMONA, Israel, August 5, 2020-- GentiBio, Inc., an emerging biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, announced today it has closed a $20 million seed funding led by OrbiMed, Novartis …